Drug Trial Radar · NCT06234956
Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
Jun 8, 2023
Primary completion
Sep 9, 2025
Study completion Sep 9, 2025
Sponsor
- Lead sponsor
- Hipra Scientific, S.L.UIndustry
- Sponsor type
- Industry
- Collaborators
- Veristat, Inc.; VHIR; Asphalion
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
Conditions
- SARS CoV 2 Infection
Interventions
BIMERVAXBiological
One dose of 40μg of BIMERVAX, administered intramuscularly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in immunogenicity against Omicron BA.1Time frame: 14 days
- Changes in immunogenicity against Omicron BA.1Time frame: 14 days
- Incidence of solicited local and systemic reactions (Safety and tolerability of PHH-1V)Time frame: 7 days
- Incidence of unsolicited local and systemic adverse events (Safety and tolerability of PHH-1V)Time frame: 28 days
- Incidence of related adverse events and serious adverse events (Safety and tolerability of PHH-1V)Time frame: 1 year
- Incidence of adverse events of special interest (Safety and tolerability of PHH-1V)Time frame: 1 year
- Incidence of related medically attended adverse events (Safety and tolerability of PHH-1V)Time frame: 1 year
- Incidence of Grade 2, Grade 3 and Grade 4 changes in safety laboratory parameters (Safety and tolerability of PHH-1V)Time frame: 14 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Hospital Vall Hebron
Barcelona, Barcelona, Spain
CAP Centelles
Centelles, Barcelona, Spain
Hospital Josep Trueta
Girona, Girona, Spain
CAP Peralada
Peralada, Girona, Spain
Hospital HM Montepríncipe
Boadilla del Monte, Madrid, Spain
Hospital La Paz
Madrid, Madrid, Spain
Hospital HM Puerta del Sur
Móstoles, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.